See our latest insights on the current complex reality of clinical trials and how pharma companies can reimagine clinical trials.
Clinical trials are critical for the delivery of safe new medicines to the marketplace. But as the coronavirus pandemic has highlighted, it’s a complex, drawn-out process. The pharmaceutical industry needs a new and innovative approach to clinical trials – one that will ensure patients have access to lifesaving treatments regardless of black swan events like the global pandemic.
Under these conditions, the pharmaceutical industry needs to engage in innovation, and modernize their practices. Particularly gaining ground are decentralized trials, where the trial process is moved into the patients’ home, rather than a traditional trial center. Decentralized trials are becoming increasingly possible thanks to technologies such as artificial intelligence, machine learning, and cloud computing, and it’s also sparking a renewed drive for patient centricity across the health sector.
In this whitepaper, we explore the current complex reality of the clinical trials landscape and how pharmaceutical companies can reimagine clinical trials.